Registry Study for Personalized Cancer Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02508662|
Recruitment Status : Recruiting
First Posted : July 27, 2015
Last Update Posted : February 16, 2018
To evaluate the anti-cancer activity of commercially available, targeted anti-cancer therapies used off-label for treatment in patients with advanced solid cancer with known genomic aberrations.
To determine outcomes of patients who were treated with matched targeted anti-cancer therapies based on known genomic aberrations.
To obtain treatment related adverse events in patients with advanced solid tumor who were treated with off -label targeted therapies.
To determine co-genomic aberrations that may contribute to treatment response or resistance mechanisms.
To determine feasibility of detecting the genomic alterations in plasma, and the genomic evolution of circulating biomarkers.
|Condition or disease||Intervention/treatment|
|Advanced Cancers Solid Tumors||Other: Review of Screening Tests and Molecular Test Results|
Study Treatment Assignment:
If you are found to be eligible to take part in this study, the study doctor will review the test results in your medical records that were previously performed as part of your routine care. The results of the testing may be helpful in managing your treatment and may also help the doctor to find effective off-label use of FDA approved therapies for the type of cancer you have.
After reviewing the screening tests and the molecular test results in your medical records, the study staff and your study doctor will work together to find an off-label use for an FDA approved therapy that is best for you. You may receive a single therapy or a combination of therapies. You and the study doctor will discuss this.
The study doctor or study staff will tell you which drug(s) you will be taking, the dose of the study drug(s), and how often you should take them. You will sign a separate consent form that explains in more detail how the study drug(s) are administered and the potential benefits and side effects of taking the study drug(s).
While you are receiving treatment and during follow-up, you will have your routine, standard of care clinic visits and routine tests so that the doctor may check the status of the disease to learn if the therapy chosen to treat the disease is having any effect. Information from these routine visits will be collected and stored by the study staff. The timing of these visits will depend on the type of therapy you receive.
During every cycle of therapy (about every 3-4 weeks):
- You will have a physical exam.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- If your doctor thinks it is needed, urine will be collected for routine tests.
- If your doctor thinks it is needed, you will have an EKG to check the health of your heart.
After even numbered cycles (2, 4, 6, and so on), or more often if the doctor thinks is it needed, you will have the same imaging scan(s) which were done during Screening to check the status of the disease.
This is an investigational study.
Up to 100 participants will be enrolled in this study. All will take part at MD Anderson.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Registry Study for Personalized Cancer Therapy|
|Actual Study Start Date :||July 2015|
|Estimated Primary Completion Date :||July 2023|
|Estimated Study Completion Date :||July 2024|
Advanced Cancer (Refractory) with Genomic Mutation
Participants with advanced cancer who have exhausted standard treatment option and have no potential clinical trial available, and who have potentially actionable alterations on genomic profiling.
Other: Review of Screening Tests and Molecular Test Results
Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
- Tumor Response [ Time Frame: 8 weeks ]
Evaluation of tumor: the same imaging technique used during the initial evaluation or more sophisticated studies performed once after 2 cycles.
Patients with measurable disease assessed by standard RECIST (Version 1.1).
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02508662
|Contact: Funda Meric-Bernstam, MD||713-745-4453|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Funda Meric-Bernstam, MD||M.D. Anderson Cancer Center|